Thursday, May 27, 2010 2:05:36 AM
Seconding the motion about showing a little respect --
I also find it tiresome to see people referring to Dr. Harris as Eva. Would you refer to Einstein as Albert? As an example closer to home, I don't see people referring to Dr. Seymour as "Gene" very often, unless they've actually personally communicated with him. He's often referred to here as "Seymour," which is appropriate (and respectful) as per most newspaper style guides.
By the way, I also have a Ph.D. and I also ask people to call me by my first name -- but WE HAVE NOT MET HER personally, and it's just rude and demeaning to call her by her first name on a forum that is read by hundreds or thousands of people.
I also find it tiresome to see people referring to Dr. Harris as Eva. Would you refer to Einstein as Albert? As an example closer to home, I don't see people referring to Dr. Seymour as "Gene" very often, unless they've actually personally communicated with him. He's often referred to here as "Seymour," which is appropriate (and respectful) as per most newspaper style guides.
By the way, I also have a Ph.D. and I also ask people to call me by my first name -- but WE HAVE NOT MET HER personally, and it's just rude and demeaning to call her by her first name on a forum that is read by hundreds or thousands of people.
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
